[
    [
        {
            "time": "2018-12-12",
            "original_text": "Why Arrowhead Pharmaceuticals Surged 11% Higher Today",
            "features": {
                "keywords": [
                    "Arrowhead Pharmaceuticals",
                    "Surged",
                    "11%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 9,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-12-12",
            "original_text": "Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Gains",
                    "Lags Market"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-12-12",
            "original_text": "J&J Reportedly Willing To Pay $400 Million-Plus In Hip-Device Cases",
            "features": {
                "keywords": [
                    "J&J",
                    "$400 Million",
                    "Hip-Device Cases"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-12-12",
            "original_text": "J&J says its psoriasis drug superior to Novartis treatment in study",
            "features": {
                "keywords": [
                    "J&J",
                    "psoriasis drug",
                    "superior",
                    "Novartis"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-12-12",
            "original_text": "5 Pharma Stocks That Could Cure Ailing Portfolios in 2019",
            "features": {
                "keywords": [
                    "Pharma Stocks",
                    "Cure",
                    "Ailing Portfolios",
                    "2019"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-12-12",
            "original_text": "Health Care Sector Update for 12/12/2018: XBIT, SGYP, NBIX, MRNS, JNJ, PFE, MRK, ABT, AMGN",
            "features": {
                "keywords": [
                    "Health Care Sector",
                    "Update",
                    "XBIT",
                    "SGYP",
                    "NBIX",
                    "MRNS",
                    "JNJ",
                    "PFE",
                    "MRK",
                    "ABT",
                    "AMGN"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-12-12",
            "original_text": "Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya",
            "features": {
                "keywords": [
                    "Portola",
                    "Down",
                    "CHMP",
                    "Defers",
                    "Review Date",
                    "Ondexxya"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-12-12",
            "original_text": "Here's How to Survive a Stock Market Crash",
            "features": {
                "keywords": [
                    "Survive",
                    "Stock Market Crash"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 9,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-12-12",
            "original_text": "Do Analysts See Any Upside for Regeneron Stock?",
            "features": {
                "keywords": [
                    "Analysts",
                    "Upside",
                    "Regeneron Stock"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-12-12",
            "original_text": "What Regeneron Pharmaceuticals’ Bottom Line Indicates",
            "features": {
                "keywords": [
                    "Regeneron Pharmaceuticals",
                    "Bottom Line"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]